Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives

CITIUS ONCOLOGY, INC.

2025-Q1 EPS reported -$0.09

Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.
G&A expenses rose to $3.3M from $1.5M on pre-commercial launch costs for LYMPHIR.
Engaged Jefferies as exclusive financial advisor to evaluate strategic alternatives; active discussions underway.
Received permanent J-code J9161 for LYMPHIR effective April 1, 2025; launch on track for H1 2025.
R&D expenses were $1.3M, up from $1.2M, supporting two investigator-initiated trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.